HTFL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HT

Mkt Cap

$4.20B

Volume

784.72K

Next Earnings

November 11th

Loading chart

HT

HTFLHeartflow, Inc. Common Stock

HTFL

Pay with—

Available Balance0.00

HT

Mkt Cap

$4.20B

Volume

784.72K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive LandscapeThe global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.GlobeNewswire Inc. · Sep 17, 2026

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly HalfHeartflow announced one-year results from the independent FUSION trial showing its FFRCT Analysis reduced unnecessary invasive heart procedures by 44% when added to standard CCTA scans. The Dutch government-funded randomized controlled trial of 528 patients demonstrated that Heartflow's AI technology safely bridges diagnostic gaps in coronary artery disease evaluation, maintaining identical revascularization rates while significantly reducing diagnostic catheterizations.GlobeNewswire Inc. · Aug 28, 2026

Why Heartflow Stock Soared TodayHeartflow stock jumped 35.70% after the medical diagnostics company raised its full-year revenue guidance to $246-250 million (40-42% growth) from a prior forecast of 29-32% growth. The company's Q2 revenue surged 48% year-over-year to $64.1 million, with adjusted gross margins improving to 83.3% from 75.6%, demonstrating improving profitability and operational scalability.The Motley Fool · Aug 14, 2026

What Does the HeartFlow CEO's Sale of Over 20,000 Company Shares Mean for Investors?HeartFlow CEO John Farquhar sold 22,562 shares worth ~$626,100 on July 10, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established in September 2025. The sale represents only a 5% reduction in his direct holdings, and he retains 435,373 shares valued at $11.63 million, indicating aligned interests with shareholders. The transaction is not considered a red flag given its non-discretionary nature and the company's strong Q1 performance with 41% year-over-year revenue growth.The Motley Fool · Jul 15, 2026

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.The Motley Fool · Jul 8, 2026

16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapVentripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, Ventripoint's vendor-agnostic technology delivers MRI-level accuracy from standard echocardiograms. The alliance will fund and place four VMS+ units, signaling commercial validation in a rapidly growing AI cardiology market projected to reach $14.2 billion by the mid-2030s.Benzinga · Jun 16, 2026

Stanford Trustees Exited HeartFlow Stock for $8.5 Million. Here's What That Means for Investors.Stanford University's Board of Trustees completely exited their HeartFlow position by selling 312,234 shares for $8.48 million in Q1 2026. Despite the exit, the article suggests this was a strategic decision to lock in gains rather than a sign of concern, as HeartFlow's business fundamentals remain strong with 40% YoY revenue growth. However, the company remains unprofitable with a net loss of $116.8 million in 2025.The Motley Fool · May 8, 2026

How Decentralized AI is Unlocking Value in Cardiac DiagnosticsFive companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration with Mount Sinai on AI-ECG algorithms, Heartflow's new clinical registry data, Hyperfine's breakthrough stroke detection results, and GE Healthcare's role in the EU's COMPASS cardiotoxicity initiative.Benzinga · Mar 27, 2026

What Investors Should Know About One HeartFlow Insider's $2 Million Stock SaleHeartFlow's chief medical officer Rogers Campbell sold 64,533 shares worth approximately $1.66 million on March 19, 2026, reducing his direct holdings by 72.8%. The sale appears routine and executed under a pre-arranged plan rather than signaling loss of confidence. HeartFlow reported strong 2025 revenue growth of 40% year-over-year to $176 million, with 2026 guidance of $218-222 million, though the company remains unprofitable.The Motley Fool · Mar 25, 2026

Is Recent IPO Stock Heartflow a Buy After a Director Scooped Up Shares Worth Over $1 Million?HeartFlow director Jeffrey Lightcap purchased 40,000 shares worth $1.05 million on December 16, 2025, just after the stock hit a 52-week low of $25.38. While the company shows strong revenue growth of 41% year-over-year in Q3, it faces significant profitability challenges with net losses expanding to $50.9 million. The insider buy suggests confidence in the company's future, but the stock remains risky for investors given its recent IPO status and limited public company track record.The Motley Fool · Dec 28, 2025

to start trading

HT

HTFLHeartflow, Inc. Common Stock

HTFL

Pay with—

Available Balance0.00

Your PositionYou don't own any HTFL yet.

Related Tickers

Earnings